Shining on Major News : TIBCO Software (NASDAQ:TIBX), Youku Tudou (NYSE:YOKU), Apple Inc. (NASDAQ:AAPL), Concert Pharmaceuticals (NASDAQ:CNCE), KB Financial Group, Inc. (NYSE:KB),

TIBCO Software Inc. (NASDAQ:TIBX) was gaining Wednesday following reports that private equity firms are competing to buy the business software company. Vista Equity Partners and Thomas Bravo are a part of a small group of private equity firms vying for the opportunity to acquire Tibco, according to Reuters. TIBCO Software Inc. (NASDAQ:TIBX) belongs to Technology sector. Its net profit margin is 7.30% and weekly performance is -2.41%. On last trading day company shares ended up $20.26. TIBCO Software Inc. (NASDAQ:TIBX) distance from 50-day simple moving average (SMA50) is -1.28%.

Youku Tudou Inc (NASDAQ:YOKU) has received a consensus rating of “Hold” from the seventeen brokerages that are presently covering the company, AR Network reports. Two analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company. Youku Tudou Inc. (NYSE:YOKU) shares advanced 0.11% in last trading session and ended the day at $18.08. YOKU Gross Margin is 19.10% and its return on assets is -5.40%. Youku Tudou Inc. (NYSE:YOKU) quarterly performance is -17.78%.

Apple Inc. (NASDAQ:AAPL) started selling its latest smartphone iPhone 6 and iPhone 6 Plus just last Friday, however, user complaints have started pouring in that the new devices bend under pressure. Apple Inc. (NASDAQ:AAPL) belongs to Consumer Goods sector. Its net profit margin is 21.60% and weekly performance is 0.17%. On last trading day company shares ended up $101.75. Apple Inc. (NASDAQ:AAPL) distance from 50-day simple moving average (SMA50) is 3.26%.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced that it has initiated a Phase 1 clinical trial of CTP-730, a novel product candidate that is being developed under its strategic collaboration with Celgene Corporation. Concert will conduct the randomized, double-blind, single ascending dose Phase 1 clinical trial designed to assess the safety, tolerability and pharmacokinetics of CTP-730. The study is expected to enroll up to 40 healthy subjects. The Phase 1 clinical program will also evaluate multiple ascending doses of CTP-730 and is expected to be completed in 2015. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) ended the last trading day at $13.94. Company weekly volatility is calculated as 4.98% and price to cash ratio as 2.55. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) showed a weekly performance of 1.09%.

KB Financial Group, Inc. (NYSE:KB)’s board dismissed the company’s top executive after he refused to step down following his suspension by South Korean regulators. The board of the nation’s second-largest financial group by market value agreed to remove Lim Young Rok, 59, from his chairman and chief executive officer posts at a meeting late yesterday, Seoul-based KB Financial said in a statement. His dismissal will take effect immediately to ensure “early stabilization and business normalization,” it said. KB Financial Group, Inc. (NYSE:KB) shares advanced 2.13% in last trading session and ended the day at $38.78. KB return on assets is 0.50%. KB Financial Group, Inc. (NYSE:KB) quarterly performance is 13.39%.